{"id":694,"date":"1998-03-01T12:02:00","date_gmt":"1998-03-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/langzeiteffekte-von-finasterid-bei-benigner-prostatahyperplasie-bph"},"modified":"1998-03-01T12:02:00","modified_gmt":"1998-03-01T11:02:00","slug":"langzeiteffekte-von-finasterid-bei-benigner-prostatahyperplasie-bph","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/langzeiteffekte-von-finasterid-bei-benigner-prostatahyperplasie-bph","title":{"rendered":"Langzeiteffekte von Finasterid bei benigner Prostatahyperplasie (BPH)"},"content":{"rendered":"<p>Finasterid hemmt die 5-Alpha-Reduktase, die in der Prostata die Umwandlung von Testosteron in das aktivere Dihydrotestosteron katalysiert. In fr\u00fcheren Mitteilungen haben wir \u00fcber dieses neue antiandrogene Behandlungsprinzip der BPH bereits berichtet (AMB 1993, 27, 6; 1995, 29, 75; 1996, 30, 78). Die Mitteilung 1996 betraf eine vergleichende Studie zwischen Finasterid und dem h\u00e4ufiger angewandten Prinzip [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Finasterid hemmt die 5-Alpha-Reduktase, die in der Prostata die Umwandlung von Testosteron in das aktivere Dihydrotestosteron katalysiert. In fr\u00fcheren Mitteilungen haben wir \u00fcber dieses neue antiandrogene Behandlungsprinzip der BPH bereits berichtet (AMB 1993, 27, 6; 1995, 29, 75; 1996, 30, 78). Die Mitteilung 1996 betraf eine vergleichende Studie zwischen Finasterid und dem h\u00e4ufiger angewandten Prinzip [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1058,1474,1090,1734],"class_list":["post-694","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alpharezeptoren-blocker","tag-finasterid","tag-prostatahyperplasie","tag-terazosin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=694"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/694\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}